1型糖尿病治療的新前沿
作者：
小柯機器人發布時間：2019/12/16 14:26:53
美國加州大學舊金山分校Mark S. Anderson等研究人員展望了1型糖尿病治療的新前沿。該綜述論文於2019年12月12日在線發表於國際一流學術期刊《細胞—代謝》。
研究人員表示，1型糖尿病是由免疫介導的胰島β細胞破壞引起的一種自身免疫疾病，導致終生絕對胰島素缺乏。
近一個世紀以來，胰島素替代療法一直是大多數患有這種疾病的人的唯一療法。技術上的最新進展以及我們對β細胞發育、葡萄糖代謝以及該疾病潛在的免疫發病機制的了解已促進了新的治療和預防方法。
免疫療法的發展已經改變，轉為靶向具有耐受性的胰島特異性免疫途徑，從而推動了療法的發展。
這些療法可預防或逆轉該疾病，同時避免了過去療法中的廣泛免疫抑制毒性。
附：英文原文
Title: New Frontiers in the Treatment of Type 1 Diabetes
Author: Jeremy T. Warshauer, Jeffrey A. Bluestone, Mark S. Anderson
Issue&Volume: December 12, 2019
Abstract: ype 1 diabetes is an autoimmune disease caused by the immune-mediated destruction of pancreatic β cells that results in lifelong absolute insulin deficiency. For nearly a century, insulin replacement has been the only therapy for most people living with this disease. Recent advances in technology and our understanding of β cell development, glucose metabolism, and the underlying immune pathogenesis of the disease have led to innovative therapeutic and preventative approaches. A paradigm shift in immunotherapy development toward the targeting of islet-specific immune pathways involved in tolerance has driven the development of therapies that may allow for the prevention or reversal of this disease while avoiding toxicities associated with historical approaches that were broadly immunosuppressive. In this review, we discuss successes, failures, and emerging pharmacological therapies for type 1 diabetes that are changing how we approach this disease, from improving glycemic control to developing the 「holy grail」 of disease prevention.
DOI: 10.1016/j.cmet.2019.11.017
Source: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(19)30624-2